Products

Products

Evaclin

Evaclin
Brand Name: Evaclin
Generic Name: CLINDAMYCIN PHOSPHATE
Strength: 150MG/ML and 300MG/ML
Volume: 2ml And 4ml
Therapeutic category: LINCOMYCIN ANTIBIOTICS

Description: Evaclin is a clear, colorless to almost colorless solution. It contains 150mg/ml of Clindamycin and it belongs to a group of medicines called antibiotics. Clindamycin is usually reserved for the treatment of serious infections, especially when other antibiotics have been unable to clear the infection and when the infection is caused by bacteria that are sensitive to Clindamycin.

How EVACLIN works:

Mechanism of action: Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. It binds to the 50S ribosomal subunit and affects both ribosome assembly and the translation process. Although it is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin. At usual doses, clindamycin exhibits bacteriostatic activity.

Therapeutic Indication:

Antibacterial. Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated for the treatment of severe infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp and microaerophilic streptococci.

Dosage and Administration:

I.M. or I.V. administration

Posology

Adults:

  • Serious infections: 600mg-1.2g/day in two, three or four equal doses.
  • More severe infections: 1.2-2.7g/day in two, three or four equal doses.
  • Single I.M. injections of greater than 600mg are not recommended nor is the administration of more than 1.2g in a single one-hour infusion.
  • For more serious infections, these doses may be increased. In life-threatening situations, doses as high as 4.8g daily have been given I.V. to adults.

Elderly: The half-life, volume of distribution and clearance, and extent of absorption are not altered by increased age.

Pediatric population (over 1 month of age):

  • Serious infection: 15-25 mg/kg/day in three or four equal doses.
  • More serious infections: 25-40 mg/kg/day in three or four equal doses. In severe infections, it is recommended that children be given no less than 300mg/day regardless of body weight.

Method of administration:

  • Evaclin should be used undiluted for I.M. administration.
  • Evaclin must be diluted prior to I.V. administration and should be infused over at least 10-60 minutes.
  • The concentration of clindamycin in diluent for infusion should not exceed 18 mg/ml and infusion rates should not exceed 30mg per minute.

Prescribing Information: PDF Download

The details of our product are included from the finalized insert available for our products.